Most of my portfolio is long term holds ...like AMZN for over 10 yrs .
I do speculate in some areas of biotech and tech as you can see on " IHUB boards posted on " .......but thats 20% of my portfolio at most .
So I'm pretty risk adverse
EYPT looks more risk than OCUL ...in my layman analysis . It's down 17% in the past week . If it went below $6.8 I'd probably be out of it if I owned it ..
Re assessing / selling half on a 20-25 % individual stock pull back has saved my portfolio multiple times over the years .
There may be more upside in EYPT vs OCUL ...but its more risk then I want to take .
I'm more willing to take risk with ARDX and UNCY ( UNCY is very risky ) because my wife has patients on serum phosphorous drugs ...and most are no where near serum pho goal. She and the Nephrologists she works with want these drugs for their patients . Each of these have issues ...as you can see being discussed on those boards .
Good luck
Kiwi
I do speculate in some areas of biotech and tech as you can see on " IHUB boards posted on " .......but thats 20% of my portfolio at most .
So I'm pretty risk adverse
EYPT looks more risk than OCUL ...in my layman analysis . It's down 17% in the past week . If it went below $6.8 I'd probably be out of it if I owned it ..
Re assessing / selling half on a 20-25 % individual stock pull back has saved my portfolio multiple times over the years .
There may be more upside in EYPT vs OCUL ...but its more risk then I want to take .
I'm more willing to take risk with ARDX and UNCY ( UNCY is very risky ) because my wife has patients on serum phosphorous drugs ...and most are no where near serum pho goal. She and the Nephrologists she works with want these drugs for their patients . Each of these have issues ...as you can see being discussed on those boards .
Good luck
Kiwi
Recent OCUL News
- Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:19:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:18:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:17:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:13:43 PM
- Ocular Therapeutix™ to Participate in March Investor Conferences • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:23:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:21:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:18:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:16:55 PM
- Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations • GlobeNewswire Inc. • 02/23/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2026 09:36:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:31:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:29:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:28:28 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 11:13:23 PM
- Ocular Therapeutix plunges 35% despite positive wet AMD Phase 3 data • IH Market News • 02/17/2026 03:35:10 PM
- Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 • GlobeNewswire Inc. • 02/13/2026 10:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 09:33:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 09:20:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 09:18:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2026 09:16:06 PM
